David C Rubinsztein Selected Research

Mutant Proteins (Protein, Mutant)

1/2020	cGMP via PKG activates 26S proteasomes and enhances degradation of proteins, including ones that cause neurodegenerative diseases.
10/2015	Lack of Neuronal IFN-β-IFNAR Causes Lewy Body- and Parkinson's Disease-like Dementia.
5/2012	Autophagy and polyglutamine diseases.
3/2012	α-Synuclein levels affect autophagosome numbers in vivo and modulate Huntington disease pathology.
4/2010	Chemical inducers of autophagy that enhance the clearance of mutant proteins in neurodegenerative diseases.
9/2008	Huntington's disease: degradation of mutant huntingtin by autophagy.
9/2008	Small molecule enhancers of autophagy for neurodegenerative diseases.
4/2006	Inositol and IP3 levels regulate autophagy: biology and therapeutic speculations.
4/2003	Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David C Rubinsztein Research Topics

Disease

64	Huntington Disease (Huntington's Disease) 01/2022 - 05/2002
61	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 05/2002
22	Parkinson Disease (Parkinson's Disease) 12/2022 - 05/2002
21	Alzheimer Disease (Alzheimer's Disease) 10/2021 - 05/2002
15	Starvation 12/2021 - 04/2010
9	Oculopharyngeal Muscular Dystrophy 03/2011 - 04/2002
8	Spinocerebellar Ataxias (Spinocerebellar Ataxia) 01/2022 - 01/2006
7	Tauopathies 01/2020 - 01/2006
7	Proteostasis Deficiencies 01/2018 - 11/2004
5	Neoplasms (Cancer) 12/2020 - 07/2011
4	Machado-Joseph Disease (Spinocerebellar Ataxia Type 3) 01/2017 - 10/2006
3	Dementia (Dementias) 12/2022 - 02/2006
3	Disease Progression 01/2020 - 04/2003
3	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2020 - 09/2008
3	Infections 01/2019 - 09/2011
2	Carcinogenesis 01/2022 - 04/2015
2	Inflammation (Inflammations) 10/2017 - 10/2015
2	Mitochondrial Diseases (Mitochondrial Disease) 12/2015 - 06/2015
2	Frontotemporal Dementia (Semantic Dementia) 03/2014 - 01/2006
2	Muscle Weakness 06/2010 - 01/2006
2	Communicable Diseases (Infectious Diseases) 11/2007 - 06/2007
1	Synucleinopathies 12/2022
1	Multiple System Atrophy 12/2022
1	Oculocerebrorenal Syndrome (Lowe Syndrome) 01/2021
1	Congenital Structural Myopathies (Centronuclear Myopathy) 01/2020
1	Hypoxia (Hypoxemia) 01/2018
1	Movement Disorders (Movement Disorder) 12/2017
1	Ataxia (Dyssynergia) 09/2017
1	Non-alcoholic Fatty Liver Disease 02/2016
1	Neuroblastoma 12/2015
1	B-Cell Lymphoma (Lymphoma, B Cell) 12/2013
1	Macular Degeneration (Age-Related Maculopathy) 08/2012

Drug/Important Bio-Agent (IBA)

75	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2002
38	polyglutamineIBA 10/2020 - 05/2002
9	Mutant Proteins (Protein, Mutant)IBA 01/2020 - 04/2003
7	SynucleinsIBA 12/2022 - 04/2006
7	Sirolimus (Rapamycin)FDA Link 02/2010 - 06/2004
6	Glucose (Dextrose)FDA LinkGeneric 12/2021 - 02/2006
6	Protein AggregatesIBA 10/2021 - 05/2002
6	Huntingtin ProteinIBA 10/2020 - 05/2003
6	polyalanineIBA 03/2011 - 01/2006
5	alpha-SynucleinIBA 08/2010 - 01/2006
4	Ataxin-3IBA 01/2017 - 10/2006
4	Poly(A)-Binding Protein IIIBA 03/2011 - 04/2002
4	LithiumIBA 01/2008 - 09/2002
3	Phosphotransferases (Kinase)IBA 12/2021 - 01/2019
3	LipidsIBA 12/2021 - 01/2019
3	Amyloid (Amyloid Fibrils)IBA 10/2021 - 10/2017
3	Amyloid beta-PeptidesIBA 10/2020 - 02/2005
3	TrehaloseIBA 02/2016 - 01/2006
2	Mechanistic Target of Rapamycin Complex 1IBA 01/2021 - 04/2011
2	InterferonsIBA 01/2020 - 10/2015
2	Carrier Proteins (Binding Protein)IBA 01/2019 - 06/2010
2	Rilmenidine (Hyperium)IBA 12/2017 - 06/2010
2	Beclin-1IBA 01/2017 - 08/2012
2	BuffersIBA 08/2015 - 04/2010
2	AntioxidantsIBA 11/2012 - 09/2010
2	Pharmaceutical PreparationsIBA 09/2011 - 10/2005
2	Apolipoproteins E (ApoE)IBA 09/2010 - 09/2006
2	UbiquitinIBA 01/2010 - 11/2007
2	temsirolimus FDA Link 01/2010 - 06/2004
2	TOR Serine-Threonine KinasesIBA 01/2010 - 06/2007
2	Dyneins (Dynein)IBA 10/2005 - 07/2005
2	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 01/2005 - 03/2004
2	Cholinergic Agents (Cholinergics)IBA 01/2005 - 03/2004
1	NF-kappa B (NF-kB)IBA 01/2022
1	CateninsIBA 01/2022
1	Phospholipids (Phosphatides)FDA LinkGeneric 12/2021
1	phosphatidylinositol 3,5-diphosphateIBA 12/2021
1	Adenosine Triphosphatases (ATPase)IBA 01/2021
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2021
1	p300-CBP-associated factorIBA 01/2021
1	Mechanistic Target of Rapamycin Complex 2IBA 12/2020
1	Dynamin IIIBA 01/2020
1	Amino Acids FDA Link 01/2020
1	tau Proteins (tau Protein)IBA 01/2020
1	Phosphodiesterase 5 InhibitorsIBA 01/2020
1	Felodipine (Agon)FDA LinkGeneric 01/2019
1	Antihypertensive Agents (Antihypertensives)IBA 01/2019
1	L-Type Calcium Channels (Dihydropyridine Receptor)IBA 01/2019
1	Adenosine Monophosphate (AMP)IBA 02/2016
1	DisaccharidesIBA 02/2016
1	Protein Kinases (Protein Kinase)IBA 02/2016
1	Heterogeneous Nuclear Ribonucleoprotein A1IBA 12/2015
1	CytokinesIBA 10/2015
1	Annexin A2 (Annexin II)IBA 08/2015
1	Small Interfering RNA (siRNA)IBA 05/2015
1	Carbamazepine (Tegretol)FDA LinkGeneric 02/2015
1	Phosphatidylinositols (Phosphatidylinositol)IBA 09/2014
1	Vesicular Transport Adaptor ProteinsIBA 09/2014
1	DNA-Binding Proteins (DNA Binding Protein)IBA 03/2014
1	Mitogen-Activated Protein Kinase 8IBA 12/2013
1	diazonaphthalenedisulfonic acid (NDS)IBA 11/2013
1	Complement Factor B (Factor B)IBA 08/2012
1	Complement C3 (C3 Complement)IBA 08/2012
1	Complement C2 (Complement Component 2)IBA 08/2012
1	Complement System Proteins (Complement)IBA 08/2012

Therapy/Procedure

12	Therapeutics 10/2021 - 01/2006
3	Drug Therapy (Chemotherapy) 05/2015 - 11/2004
1	Immunomodulation 10/2015